AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tourmaline jumps 57% after Novartis to buy firm for $1.4B
ByAinvest
Tuesday, Sep 9, 2025 4:14 am ET1min read
Tourmaline jumps 57% after Novartis to buy firm for $1.4B
Swiss pharmaceutical giant Novartis AG (NVS) has announced the acquisition of Tourmaline Bio Inc. (TRML) for approximately $1.4 billion in cash. The deal, which has been approved by the boards of both companies, is expected to close in the fourth quarter of 2025 [2].The acquisition price of $48 per share represents a 59% premium to Tourmaline's closing price on September 8, 2025, the last trading day before the announcement. This premium has driven Tourmaline's stock price to jump by 57% in after-hours trading, closing at $55.95 [3].
Tourmaline's lead drug candidate, pacibekitug, is a long-acting antibody targeting the IL-6 protein, believed to play a key role in cardiovascular inflammation. The drug has shown potential in reducing inflammation tied to heart disease, as evidenced by mid-stage trial data released in May [5].
Novartis, through this acquisition, aims to bolster its biotechnology pipeline and enhance its competitive edge in the sector. The deal underscores the potential of pacibekitug, which could represent a breakthrough in addressing residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD) [4].
Analysts have provided mixed projections for Novartis. The average one-year price target for Novartis AG is $117.31, with a range of estimates from $100.00 to $134.00 [1]. The consensus recommendation from brokerage firms is a "Hold," reflecting a neutral outlook among analysts [1].
GuruFocus estimates a GF Value of $133.14 for Novartis AG, suggesting a potential 3.44% upside from its current trading price of $128.71 [1].
References:
[1] https://www.gurufocus.com/news/3100274/novartis-nvs-acquires-tourmaline-bio-for-14-billion-in-cash
[2] https://www.investing.com/news/stock-market-news/novartis-to-acquire-tourmaline-bio-for-14-billion-4230459
[3] https://www.nasdaq.com/articles/tourmaline-bio-agrees-be-acquired-novartis-14-bln-deal-stock
[4] https://seekingalpha.com/news/4493234-novartis-to-acquire-tourmaline-bio-in-14b-all-cash-deal
[5] https://www.statnews.com/2025/09/09/novartis-tourmaline-bio-heart-disease-acquisition-pacibekitug/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet